Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older

Borissovа, Anna-Maria; Rashkov, Rasho; Boyanov, Mihail; Shinkov, Alexander; Popivanov, P; Temelkova, Nataliya; Vlahov, Jordan; Gavrailova, Masha

doi:10.1007/s11657-011-0064-x

Cited by 12 publications

(23 citation statements)

References 24 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone resorption is a natural phenomenon and can occur due to old age. 12 Osteoporosis affects men and women of any age, more commonly postmenopausal women [12][13][14] and women over 50 years of age 5 . Osteoporosis is more common in women than in men: 50% of women 14 and 25% of men aged over 50 have osteoporotic fractures 15 .…”

Section: Epidemiologymentioning

confidence: 99%

“…12,16,18 Diseases that are a risk factor for secondary osteo- AIDS, organ transplantation, and liver failure. Medications that cause osteoporosis by reducing the ability of bone to be recovered are: antidepressants, anticonvulsants, antihypertensives, glucocorticoids, diuretics, immunosuppressants, sedatives, tranquilizers, hypoglycemic agents, chemotherapeuticals against excess thyroid hormones.…”

Section: Etiologymentioning

confidence: 99%

“…Medications that cause osteoporosis by reducing the ability of bone to be recovered are: antidepressants, anticonvulsants, antihypertensives, glucocorticoids, diuretics, immunosuppressants, sedatives, tranquilizers, hypoglycemic agents, chemotherapeuticals against excess thyroid hormones. [8][9][10][11] Controllable risk factors for osteoporosis are: diet 12,16,19 , low bone mineral density, defi ciency in the intake of calcium, magnesium, vitamin D 20,21 ; low body mass index (BMI 20 kg/m 2 leads to an increased risk of fractures -2 times higher, and 16 kg/m 2 -4 times) 12 ; excessive use of alcohol 22 , caffeine 23 , sodium, smoking 24 ; environmental pollutants and heavy metals; lack of physical activity [25][26][27][28] . Vitamins B6, C and K are important for the synthesis of bone proteins.…”

Section: Etiologymentioning

confidence: 99%

“…35 Vitamin D3 at a daily dose of 800 IU with calcium (1000 mg) reduces the risk fractures in elderly. 2,4,12,[35][36][37] The recommended daily intake of vitamin D from food and supplements together: a) men and women in‚ 65 -≥ 600 IU (15 μg) per day; b) men and women over 65 years of age: ≥ 800 IU (20 μg) per day; in men and women with proven defi cit and during pregnancy 2000-4000 IU (50-100 μg) per day. All patients with osteoporosis undergoing anti-osteoporosis treatment, must receive a minimum of 800 IU of vitamin D per day, in order to ensure an optimal effect of the treatment.…”

Section: Inhibitors Of Bone Resorptionmentioning

confidence: 99%

See 3 more Smart Citations

Osteoporosis: Therapeutic Options

Ivanova¹,

Vasileva²,

Ivanova³

et al. 2016

Folia Medica

View full text Add to dashboard Cite

The definition of osteoporosis was originally formulated at a conference of the World Health Organization (WHO) in 1993 as 'a systemic skeletal disease characterized by decreased bone mass and altered micro-architecture of bone tissue, leading to enhanced bone fragility and risk of fractures'. Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and bio-mechanical properties that are required to maintain bone homeostasis. This review aims to address the currently available options in prevention and treatment of osteoporosis. Management of osteoporosis includes non-pharmacological treatment - diet rich of calcium and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy. Combination of non-pharmacological and pharmacological treatment options have to be considered for prevention of osteoporosis and minimization of the risk of fractures. Given the heterogeneity of osteoporosis syndrome and lack of significant number of comparative studies, the choice of a pharmacological agents should be individualized.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Etiologymentioning

confidence: 99%

Section: Etiologymentioning

confidence: 99%

Section: Inhibitors Of Bone Resorptionmentioning

confidence: 99%

See 2 more Smart Citations

Osteoporosis: Therapeutic Options

Ivanova¹,

Vasileva²,

Ivanova³

et al. 2016

Folia Medica

View full text Add to dashboard Cite

show abstract

“…A study in Bulgaria among women > 50 years found that the mean 10-year absolute fracture risk was 13.4 ± 9.2% (major fractures) and 2.8 ± 5.2% (HP) [17]. A study in Taiwan found that the mean 10-year probabilities of MOF or HF were 13.8% (95% confidence interval (CI) = 10.7%-16.9%) and 2.2% (95% CI = 0.8%-3.5%), respectively [18].…”

Section: Discussionmentioning

confidence: 99%

Estimation of 10 - year probability bone fracture in a selected sample of Palestinian people using fracture risk assessment tool

Aker

Taha

Zyoud

et al. 2013

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundThe Fracture Risk Assessment (FRAX) tool has been developed by the World Health Organization (WHO) to calculate 10-year probability hip fracture (HP) or major osteoporotic fracture (MOF). The objective of this study was to assess the 10-year probability of MOF and HF among a selected sample of Palestinian people.MethodsA sample of 100 subjects was studied. Dual energy X-ray absorpitometry was performed to measure bone mineral density (BMD) which was then inserted into FRAX Palestine online WHO tool to calculate the 10-year probability of MOF and HF.ResultsThe median age of participants was 61.5 years and the majority (79%) were females. The median (interquartile range) of femoral hip BMD was 0.82 (0.76-0.92) g/cm2. The mean vertebral and hip T scores were -1.41 ± 0.13 SDs and -0.91 ± 0.10 SDs respectively. About one fifth of the sample (21%) had vertebral osteoporosis and 5% had hip osteoporosis. The median (interquartile range) 10-year probability of MOF and HF based on BMD were 3.7 (2.43-6.18)%, and 0.30 (0.10-0.68)% respectively.ConclusionOsteoporosis is common among Palestinian people above 50 years old. Bone fracture prevention strategies and research should be a priority in Palestine. Using FRAX might be a helpful screening tool in primary healthcare centres in Palestine.

show abstract

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates

et al. 2017

View full text Add to dashboard Cite

SummaryPersistence with osteoporosis therapy is critical for fracture risk reduction. This observational study evaluated medication-taking behaviour of women with postmenopausal osteoporosis receiving denosumab or oral ibandronate in real-world clinical practice in Bulgaria. Compared with ibandronate, densoumab was associated with a lower discontinuation rate and greater increases in bone mineral density.PurposePersistence with osteoporosis therapy is critical for fracture risk reduction and the effectiveness of such treatments may be reduced by low persistence. Alternative therapies such as denosumab may improve persistence. This study aimed to describe medication-taking behaviour in women with osteoporosis, prescribed denosumab or oral ibandronate, in Bulgarian clinical practice.MethodsThis retrospective, observational, multicentre chart review (with up to 24 months follow-up) enrolled postmenopausal women initiating 6-monthly denosumab injection or monthly oral ibandronate treatment for osteoporosis between 1 October 2011 and 30 September 2012.ResultsOverall, 441 women were enrolled (224 had initiated denosumab, 217 had initiated ibandronate). At baseline, more women in the denosumab group than in the ibandronate group had a previous fracture (25.5 vs 17.5%; p = 0.043) and past exposure to osteoporosis therapy (19.6 vs 12.0%; p = 0.028). At 24 months, 4.5% of women receiving denosumab had discontinued therapy compared with 56.2% of women receiving ibandronate. Median time to discontinuation was longer in the denosumab group (729 days; interquartile range (IQR), 728.3–729.0) than in the ibandronate group (367 days; IQR, 354.0–484.8; p < 0.001). At 24 months, there were significantly greater changes in BMD T-scores at the lumbar spine (p < 0.001) and femoral neck (p < 0.001) in patients receiving denosumab than in those receiving ibandronate. At 24 months, persistence with denosumab was 98.7%.ConclusionThis real-world study demonstrates there is a low discontinuation rate and high persistence with denosumab. Denosumab was associated with greater BMD increases than ibandronate, which could reduce fracture risk.

show abstract

Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older

Abstract: This study is the largest epidemiological osteoporosis trial in Bulgaria to date and allows assumptions about the prevalence of osteoporosis and fractures among women aged 50 and older in our country.

Cited by 12 publications

References 24 publications

Osteoporosis: Therapeutic Options

Osteoporosis: Therapeutic Options

Estimation of 10 - year probability bone fracture in a selected sample of Palestinian people using fracture risk assessment tool

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates

Contact Info

Product

Resources

About